Caribou Biosciences Inc
Research Caribou Biosciences Inc (CRBU) on Bullrun: market cap USD 186.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRBU
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 186.55M
- Financial periodQ1 2026
- RevenueUSD 2.40M
- Net income-USD 25.09M
- Free cash flow-USD 101.64M
Valuation Snapshot
latest market cap is USD 186.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 11.16M | -USD 148.13M | -USD 112.35M | n/a | -1.59 | USD 12.36M | USD 27.23M | USD 122.18M |
| FY2024 | USD 9.99M | -USD 149.11M | -USD 143.08M | n/a | -1.65 | USD 16.29M | USD 26.49M | USD 252.95M |
| FY2023 | USD 34.48M | -USD 102.07M | -USD 104.90M | n/a | -1.38 | USD 51.16M | USD 27.11M | USD 368.40M |
| FY2022 | USD 13.85M | -USD 99.42M | -USD 97.42M | n/a | -1.64 | USD 58.34M | USD 27.97M | USD 300.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 186.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 151.28M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 146.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 506.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 383.09M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 909.37M | n/a | n/a | n/a |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Caribou Biosciences Inc's market cap?
Caribou Biosciences Inc's market capitalization is USD 186.55M.
What does Caribou Biosciences Inc do?
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.